EXACT Therapeutics, a clinical-stage precision medicine company, is pleased to announce first patient dosed in its ENACT trial.
The trial is a multi-centre, open-label Phase 2 clinical trial testing the safety and efficacy of Acoustic Cluster Therapy in combination with standard of care (modified FOLFIRINOX chemotherapy) in first line patients with borderline resectable or unresectable locally advanced pancreatic cancer.
Health Technology Insights: ZeOmega and MVP Health Care Partner to Advance Health Outcomes and Member Experience
“We are excited to have the first pancreatic cancer patient treated with ACT at our first U.S. site. More than 500,000 patients are diagnosed with pancreatic cancer each year globally, and pancreatic cancer is one of the deadliest types of cancer, with limited and often ineffective treatment options. This trial addresses the significant unmet medical need and the urge to advance novel treatment options for this patient population. We are on track with the opening of sites for patient recruitment and initial safety data are expected in 2025,” said Per Walday, Chief Executive Officer of EXACT Therapeutics.
Dosing of the first patient in the Phase 2 trial follows the announcement of positive final efficacy and safety data in the Phase 1 trial in patients with liver metastases of colorectal origin.
Health Technology Insights: Sun Life Launches Expert Cancer Review for Second Opinions
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – GlobeNewswire
